-
After 5 years of production suspension, "comeback" to market. Zhang Yi, Chairman of Yisheng Biotechnology: Vaccine adjuvants are a bottleneck in the industry. Domestic approval still needs to be accelerated
On December 8th, Yisheng Biotechnology announced that the company's independently developed new immune anti-tumor drug YS-ON-001 has completed Phase I clinical research at Tianjin Cancer Hospital. Th ... -
Just one year after going public in the United States, 67 year old founder kicked out? The leading domestic vaccine adjuvant manufacturer, Yisheng Biotechnology, is in a battle of competition
The frozen snow in Shenyang in March has not completely melted, but spring has arrived. As the car drove into Daoyi North Street, the open street scenery presented a different scene from the bustling ...